Skip to main content
    C

    CytomX Therapeutics Inc (CTMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.99
    -0.06 (-2.70%)

    Market Cap: $444.73M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CytomX Therapeutics Inc (CTMX) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect CytomX Therapeutics (CTMX) to earn -$0.39 per share in the fiscal year ending Dec 31, 2026, on revenue of $21.96M. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.63, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy337.5%
    Buy562.5%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    8

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 36.5%.

    Fiscal year ending Dec 31, 2026
    -$0.39
    EPS consensus, revenue $21.96M
    Fiscal year ending Dec 31, 2027
    -$0.50
    EPS consensus, revenue $29.98M
    Next report
    Mar 15, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.39-$0.51 to -$0.337$21.96M$11.95M to $31.30M6
    Dec 31, 2027-$0.50-$1.04 to -$0.177$29.98MN/A5

    Quarterly Estimates

    The EPS consensus is -$0.10 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.

    EPS range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.10-$0.12 to -$0.0610$5.75M$1.96M to $10.50M8
    Mar 31, 2027-$0.10-$0.13 to -$0.055$5.08MN/A4

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202710
    Quarter ending Mar 31, 202710

    EPS Trend

    The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.39-$0.39-$0.39-$0.39-$0.39N/A
    Fiscal year ending Dec 31, 2027-$0.50-$0.47-$0.47-$0.47-$0.47N/A
    Quarter ending Mar 31, 2027-$0.10-$0.13-$0.13-$0.13-$0.13N/A

    Frequently Asked Questions About CTMX

    What is the CTMX stock forecast?

    Consensus analyst estimates put CytomX Therapeutics's EPS at -$0.39 for the fiscal year ending Dec 31, 2026, on revenue of $21.96M. The consensus rating from 8 analysts is Buy.

    How do analysts rate CTMX stock?

    Of 8 analysts covering CytomX Therapeutics, 3 rate it Strong Buy, 5 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from CTMX next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.39, with estimates from -$0.51 to -$0.33 from 7 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.50, with estimates from -$1.04 to -$0.17 from 7 analysts.

    What revenue do analysts expect from CytomX Therapeutics next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $21.96M, with estimates from $11.95M to $31.30M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $29.98M.

    How many analysts cover CTMX?

    8 analysts rate CytomX Therapeutics stock, and 7 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.